Sanofi: tolebrutinib study results
(CercleFinance.com) - Sanofi announces that tolebrutinib was able to extend the time to confirmed disability progression by 31% in a Phase III study of people with non-active, secondarily progressive multiple sclerosis.
The data show that tolebrutinib, a brain-penetrant BTK inhibitor, remedies the accumulation of disability occurring independently of any disease relapse.
These results were presented today as part of a research news session at the 2024 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held in Copenhagen, Denmark.
Regulatory submissions will begin in H2 2024 worldwide.
The results of the HERCULES study unequivocally show that tolebrutinib delays the progression of disability in people with non-active MS-SP - and even induces improvement in some of them - by uniquely targeting the biological processes in the brain that drive disease progression. said Dr. Fox, Vice President of Research at the Cleveland Clinic Neurological Institute, Cleveland, Ohio, and Chairman of the HERCULES Steering Committee.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The data show that tolebrutinib, a brain-penetrant BTK inhibitor, remedies the accumulation of disability occurring independently of any disease relapse.
These results were presented today as part of a research news session at the 2024 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held in Copenhagen, Denmark.
Regulatory submissions will begin in H2 2024 worldwide.
The results of the HERCULES study unequivocally show that tolebrutinib delays the progression of disability in people with non-active MS-SP - and even induces improvement in some of them - by uniquely targeting the biological processes in the brain that drive disease progression. said Dr. Fox, Vice President of Research at the Cleveland Clinic Neurological Institute, Cleveland, Ohio, and Chairman of the HERCULES Steering Committee.
Copyright (c) 2024 CercleFinance.com. All rights reserved.